GGrantIndex
← Leaderboards

Akinyemi Oni-Orisan

University Of California, San Francisco

$3,328,938
Attributed
$3,328,938
Total exposure
3
Grants
3
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $772.5K · FY201825
$1M$750K$500K$250K$0
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$3,328,938 · 3

By mechanism

R01$1,846,400 · 1
K01$887,490 · 1
R56$595,048 · 1

Top collaborators

No co-investigators on record.

Most similar at University Of California, San Francisco

Same institution · by research overlap

Others in their field

Other Emerging Leaders on “Participant

Research focus

ParticipantVariantElectronic Health RecordLife StyleGenome-WideUnited StatesCohortEnvironmentDosePharmaceutical PreparationsGenome Wide Association StudyGenetic PolymorphismGenetic VariantUnited States National Institutes Of HealthResourcesPredicting ResponseResponseBiologicalBiomedical ResearchClinical PracticeRecommendationPharmacogenomicsSourceWhole Genome

Grant awards (12)

Genetic and social determinants of pharmacological health outcomes in ancestrally diverse populations$526,615
R01 · FY2025 · HG · contact PI
Genetic and social determinants of pharmacological health outcomes in ancestrally diverse populations$32,650
R01 · FY2025 · HG · contact PI
Genetic and social determinants of pharmacological health outcomes in ancestrally diverse populations$526,647
R01 · FY2024 · HG · contact PI
Genetic and social determinants of pharmacological health outcomes in ancestrally diverse populations (Warren)$72,540
R01 · FY2024 · HG · contact PI
Genetic and social determinants of pharmacological health outcomes in ancestrally diverse populations (Recto)$71,210
R01 · FY2024 · HG · contact PI
Genetic and social determinants of pharmacological health outcomes in ancestrally diverse populations$616,738
R01 · FY2023 · HG · contact PI
Optimization of statin regimens for atherosclerotic cardiovascular disease prevention using polygenic risk scores and real-world evidence$595,048
R56 · FY2022 · HL · contact PI
Characterization of response to lipid-modifying regimens for atherosclerotic cardiovascular disease using electronic health records$177,498
K01 · FY2022 · HL · contact PI
Characterization of response to lipid-modifying regimens for atherosclerotic cardiovascular disease using electronic health records$177,498
K01 · FY2021 · HL · contact PI
Characterization of response to lipid-modifying regimens for atherosclerotic cardiovascular disease using electronic health records$177,498
K01 · FY2020 · HL · contact PI
Characterization of response to lipid-modifying regimens for atherosclerotic cardiovascular disease using electronic health records$177,498
K01 · FY2019 · HL · contact PI
Characterization of response to lipid-modifying regimens for atherosclerotic cardiovascular disease using electronic health records$177,498
K01 · FY2018 · HL · contact PI